Bone Biologics (BBLG) Equity Ratio (2012 - 2025)

Bone Biologics (BBLG) has 14 years of Equity Ratio data on file, last reported at 0.93 in Q4 2025.

• Equity Ratio for Q4 2025 came in at 0.93, up 2.84% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.93 (up 2.84% YoY), and the FY2025 annual result was 0.93, up 2.84% from the prior year.
• Equity Ratio retreated to 0.93 in Q4 2025 per BBLG's latest filing, from 0.95 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.99 in Q1 2022 and troughed at 3293.37 in Q2 2021.
• A 5-year average of 188.29 and a median of 0.91 in 2024 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2023 and 2024: Equity Ratio tumbled 58.76% in 2023, then soared 134.2% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.99 in 2021, then dropped by 28.93% to 0.7 in 2022, then advanced by 11.07% to 0.78 in 2023, then increased by 16.03% to 0.9 in 2024, then gained by 2.84% to 0.93 in 2025.
• Business Quant data shows BBLG's Equity Ratio at 0.93 in Q4 2025, 0.95 in Q3 2025, and 0.94 in Q2 2025.